Sino takes out the rest of Merck’s partner
LaNova, which licensed a PD-1 x VEGF to Merck, is acquired by another Chinese player.
FDA red and green lights: April 2025
April saw a checkpoint inhibitor bonanza for Bristol and Akeso.
The month ahead: April’s upcoming events
AACR approaches, along with ASCO abstract titles.
Akeso keeps cadonilimab in China
The anti-PD-1 x CTLA-4 bispecific impresses in cervical cancer, but US plans are on ice.
ASCO-GI – no masking Xilio's setback
Poor efficacy clouds prospects for the company's "improved" Yervoy.
